Jennifer L Taubert's Insider Trades & SAST Disclosures
Jennifer L Taubert's most recent trade in McDonald`s Corp was a trade of 96 Phantom Stock done . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jennifer L Taubert.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 96 | 2,676 | - | - | Phantom Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 89,781 | 89,781 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 5,539 | 5,539 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,465 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 15,465 | 185,924 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 7,911 | 178,013 (0%) | 0% | 156.7 | 1,239,733 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,053 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 4,053 | 170,864 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,594 | 3,188 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,594 | 171,110 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 1,348 | 169,516 (0%) | 0% | 156.7 | 211,245 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,302 | 167,221 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,302 | 1,302 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 651 | 170,459 (0%) | 0% | 156.2 | 101,654 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 410 | 166,811 (0%) | 0% | 155.3 | 63,657 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 15,465 | 15,465 | - | - | Performance Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 58,504 | 213,355 (0%) | 0% | 100.1 | 5,853,910 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 58,504 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 47,436 | 165,919 (0%) | 0% | 153.1 | 7,263,400 | Common Stock |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 700 | 2,565 | - | - | Phantom Stock | |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 98 | 1,751 | - | - | Phantom Stock | |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 117 | 1,643 | - | - | Phantom Stock | |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 106 | 1,515 | - | - | Phantom Stock | |
| Johnson & Johnson | Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 76,981 | 76,981 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 4,782 | 4,782 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer Taubert L. | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,302 | 155,517 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Taubert L. Jennifer | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 1,302 | 2,604 | - | - | Restricted Share Units | |
| Johnson & Johnson | Taubert L. Jennifer | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 666 | 154,851 (0%) | 0% | 157.8 | 105,128 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 22,433 | 163,849 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | L. Taubert Jennifer | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 22,433 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WWC. Innovative Medicine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 13,403 | 154,215 (0%) | 0% | 157.4 | 2,109,632 | Common Stock |
| Johnson & Johnson | L. Jennifer Taubert | EVP, WWC. Innovative Medicine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 3,769 | 167,618 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 156.27 per share. | 08 Feb 2024 | 59,397 | 141,416 (0%) | 0% | 156.3 | 9,281,969 | Common Stock |
| Johnson & Johnson | L. Taubert Jennifer | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 08 Feb 2024 | 59,397 | 200,813 (0%) | 0% | 90.4 | 5,371,865 | Common Stock |
| Johnson & Johnson | L. Taubert Jennifer | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 59,397 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Taubert Jennifer L. | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 3,739 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 3,739 | 143,329 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | L. Taubert Jennifer | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,913 | 141,416 (0%) | 0% | 156.3 | 299,059 | Common Stock |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 775 | 1,400 | - | - | Phantom Stock | |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2023 | 109 | 615 | - | - | Phantom Stock | |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 96 | 503 | - | - | Phantom Stock | |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 102 | 404 | - | - | Phantom Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 64,634 | 64,634 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 21,422 | 150,159 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 10,569 | 139,590 (0%) | 0% | 162.0 | 1,712,284 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 3,906 | 3,906 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 3,570 | 130,026 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 3,570 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 1,289 | 128,737 (0%) | 0% | 162.1 | 208,921 | Common Stock |
| McDonald`s Corp | Jennifer L. Taubert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 300 | 300 | - | - | Phantom Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Sale of securities on an exchange or to another person at price $ 176.78 per share. | 22 Nov 2022 | 76,923 | 126,456 (0%) | 0% | 176.8 | 13,598,402 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2022 | 76,923 | 0 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.54 per share. | 22 Nov 2022 | 76,923 | 203,379 (0%) | 0% | 72.5 | 5,579,994 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 80,055 | 80,055 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 18,064 | 1,721 | - | - | Performance Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 18,064 | 135,297 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.89 per share. | 14 Feb 2022 | 8,841 | 126,456 (0%) | 0% | 165.9 | 1,466,633 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 4,053 | 4,053 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 3,297 | 118,423 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 3,297 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 168.85 per share. | 14 Feb 2022 | 1,190 | 117,233 (0%) | 0% | 168.9 | 200,932 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 11,429 | 119,014 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 11,429 | 0 | - | - | Performance Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.55 per share. | 12 Feb 2021 | 5,268 | 115,126 (0%) | 0% | 165.5 | 872,117 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 2,177 | 0 | - | - | Restricted Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 2,177 | 121,191 (0%) | 0% | 0 | Common Stock | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Payment of exercise price or tax liability using portion of securities received from the company at price $ 165.55 per share. | 12 Feb 2021 | 797 | 120,394 (0%) | 0% | 165.5 | 131,943 | Common Stock |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 82,127 | 82,127 | - | - | Employee Stock Options (Right to Buy) | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 11,429 | 11,429 | - | - | Performance Share Units | |
| Johnson & Johnson | Jennifer L. Taubert | EVP, WW Chair, Pharmaceuticals | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 3,739 | 3,739 | - | - | Restricted Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges